Amicus Therapeutics (FOLD) Beats Q3 Earnings and Revenue Estimates

Core Insights - Amicus Therapeutics reported quarterly earnings of $0.17 per share, exceeding the Zacks Consensus Estimate of $0.12 per share, and showing an increase from $0.10 per share a year ago, resulting in an earnings surprise of +41.67% [1] - The company achieved revenues of $169.06 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 2.61% and up from $141.52 million year-over-year [2] - The stock has underperformed the market, losing about 5.9% year-to-date compared to the S&P 500's gain of 16.5% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.16 on revenues of $179.38 million, and for the current fiscal year, it is $0.31 on revenues of $624.06 million [7] - The estimate revisions trend for Amicus Therapeutics was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Amicus Therapeutics belongs, is currently ranked in the top 39% of over 250 Zacks industries, suggesting a favorable outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]